Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.
Adult
Aged
Female
Humans
Lung Neoplasms
/ radiotherapy
Male
Mesothelioma
/ radiotherapy
Mesothelioma, Malignant
Middle Aged
Pleura
Pleural Neoplasms
/ radiotherapy
Pneumonectomy
/ methods
Radiotherapy, Adjuvant
/ methods
Radiotherapy, Image-Guided
Radiotherapy, Intensity-Modulated
/ methods
Retrospective Studies
Treatment Outcome
Extra-pleural pneumonectomy
Image-guided IMRT
Malignant pleural mesothelioma
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
18
07
2018
accepted:
14
03
2019
pubmed:
10
4
2019
medline:
11
10
2019
entrez:
10
4
2019
Statut:
ppublish
Résumé
To assess the outcome of malignant pleural mesothelioma patients treated with extra-pleural pneumonectomy (EPP) and adjuvant radiotherapy (RT), using the most advanced radiotherapeutic techniques, namely image-guided intensity-modulated RT (IG-IMRT). Fifty-four patients were analyzed. Minimum radiation dose was 50 Gy (2 Gy/fr). Planning target volume encompassed the entire hemithorax, including the ipsilateral mediastinum if interested by disease, the pericardium and diaphragm, and any drain sites. The study endpoints included loco-regional control (LRC), distant metastases free survival (DMFS), and overall survival (OS), as well as radiation-related toxicity. Major patients and treatment characteristics were the following: median age 62 years, epithelioid histology in 51 (94%) cases, locally advanced disease in 41 (90%) cases, and metastatic mediastinal lymph nodes in 27 patients (50%). Only 7 patients (13%) had gross residual disease after surgery. Chemotherapy was administered in 38 patients (70%). Median follow-up was 16 months (range 0-73 months). Median and 2-year OS were 21 months and was 43.8%, respectively. The predominant pattern of failure was distant: 34 patients (62.9%) developed some component of distant failure, and only 5 patients (9.2%) developed an isolated loco-regional recurrence. The estimates of LRC and DMFS at 2 years were 63.4% and 43.4%, respectively. Three fatal pneumonitis were documented. Other major toxicities included: Grade 2 and 3 pneumonitis in 1 and 2 cases, respectively, 1 case of bronchial fistula, pleural empyema, and Grade 3 esophagitis, respectively. Although executed in the era of high-technology radiotherapy (IG-IMRT), EPP should not be routinely performed.
Identifiants
pubmed: 30963379
doi: 10.1007/s11547-019-01030-y
pii: 10.1007/s11547-019-01030-y
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
854-859Références
Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):606-16
pubmed: 12573747
Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):768-75
pubmed: 12573764
Thorac Surg Clin. 2004 Nov;14(4):469-77, viii
pubmed: 15559053
J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3
pubmed: 18329481
J Clin Oncol. 2009 Mar 20;27(9):1413-8
pubmed: 19224855
J Clin Oncol. 2009 Jun 20;27(18):3007-13
pubmed: 19364962
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):942-9
pubmed: 20381267
Lancet Oncol. 2011 Aug;12(8):763-72
pubmed: 21723781
Radiother Oncol. 2011 Nov;101(2):303-6
pubmed: 21864923
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):362-8
pubmed: 22516382
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1278-83
pubmed: 22607910
J Thorac Oncol. 2013 Feb;8(2):238-45
pubmed: 23247629
Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):606-13
pubmed: 26281826
Ann Thorac Surg. 2015 Sep;100(3):1133
pubmed: 26354657
Lancet Oncol. 2015 Dec;16(16):1651-8
pubmed: 26538423
Radiat Oncol. 2015 Dec 30;10:267
pubmed: 26715491
Eur J Cardiothorac Surg. 2017 Nov 1;52(5):975-981
pubmed: 28482086
J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5
pubmed: 9869758